PMID- 11579632
OWN - NLM
STAT- MEDLINE
DCOM- 20011011
LR  - 20201208
IS  - 0385-0684 (Print)
IS  - 0385-0684 (Linking)
VI  - 28
IP  - 9
DP  - 2001 Sep
TI  - [Recent progress in the treatment of malignant lymphoma].
PG  - 1213-35
AB  - The present state of the art and developments in the treatment for Hodgkin's 
      disease (HD), follicular lymphoma (FL), MALT lymphoma, and aggressive 
      non-Hodgkin's lymphoma are reviewed. Four courses of ABVD therapy (ABVd therapy 
      in Japan) followed by involved-field irradiation (IFRT), and 6 to 8 courses of 
      ABVD (ABVd in Japan) are the current state art of the therapy for early stage HD 
      and advanced stage HD, respectively. High-dose chemotherapy with autologous 
      hematopoietic stem cell transplantation (auto-HSCT) is also the state of the art 
      for refractory or relapsed HD within 1 year after complete remission (CR) 
      produced by polychemotherapy. The prognosis of the patients with 3 or more 
      International Prognostic Scores (IPS) is poor. New intensified polychemotherapy 
      or auto-HSCT as up-front setting is under randomized phase III clinical trial in 
      Europe and the USA. There is no state of the art therapy for indolent lymphoma 
      including FL, or MALT. Promising results were reported from clinical studies 
      using new anti-lymphoma drugs such as rituximab, iibritumomab, or purine analogs 
      (cladribine and fludarabine), and auto-HSCT with effectively purged stem cells or 
      allogeneic HSCT. These therapeutic strategies hold a possibility of cure for 
      indolent lymphomas. Antibiotic treatment for Helicobacter pylori-positive 
      localized gastric MALT lymphoma is the state of the art therapy. However, there 
      is no standard therapy for advanced stage MALT lymphoma. Risk adapted therapy 
      using the International Prognostic Index is essential for the treatment of 
      aggressive NHL. Three courses of CHOP followed by IFRT for localized aggressive 
      NHL and 8 courses of CHOP for the low-risk group of advanced stage aggressive NHL 
      are the state of the art therapies, respectively. High-dose chemotherapy with 
      auto-HSCT is also the state of the art for sensitive relapse patients with 
      aggressive NHL. Although some clinical studies suggested that high-dose 
      chemotherapy with auto-HSCT as up-front setting for high-intermediate or 
      high-risk group aggressive NHL is more effective than conventional chemotherapy, 
      the efficacy remains to be determined. The development of new therapeutic 
      strategies with combined use of molecular targeting drugs such as rituximab, or 
      new anti-lymphoma drugs such as purine analogs, and HSCT is desired for more 
      effective therapy for refractory lymphomas.
FAU - Ogura, M
AU  - Ogura M
AD  - Department of Hematology and Chemotherapy, Aichi Cancer Center Hospital, 1-1 
      Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan.
LA  - jpn
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Gan To Kagaku Ryoho
JT  - Gan to kagaku ryoho. Cancer & chemotherapy
JID - 7810034
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Helicobacter Infections/drug therapy
MH  - Helicobacter pylori
MH  - Hematopoietic Stem Cell Transplantation
MH  - Hodgkin Disease/drug therapy/radiotherapy/*therapy
MH  - Humans
MH  - Leukemia, Lymphoid/therapy
MH  - Lymphoma/classification/*therapy
MH  - Lymphoma, B-Cell, Marginal Zone/drug therapy/microbiology/pathology
MH  - Lymphoma, Non-Hodgkin/therapy
MH  - Prognosis
MH  - Radioimmunotherapy
MH  - Recurrence
RF  - 77
EDAT- 2001/10/03 10:00
MHDA- 2001/10/12 10:01
CRDT- 2001/10/03 10:00
PHST- 2001/10/03 10:00 [pubmed]
PHST- 2001/10/12 10:01 [medline]
PHST- 2001/10/03 10:00 [entrez]
PST - ppublish
SO  - Gan To Kagaku Ryoho. 2001 Sep;28(9):1213-35.